LDE225, a Smo antagonist, combined with nilotinib, a tyrosine kinase inhibitor, may introduce a novel approach to induce the eradication of CML-LSCs.126. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.